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During the decade of the 1970s a great deal of progress 
was made in elucidating how viruses cause cancer. The 
RNA tumor viruses were shown to harbor cellular genes, 
often containing mutations, that overexpressed a pro- 
tein causing the cancer. Long-latency RNA tumor vi- 
ruses integrated next to or near a cellular gene that was 
then overexpressed and contributed to the formation of 
the tumor. By contrast, the DNA tumor viruses encoded 
their own genes that had no cellular ortholog, but were 
essential for the initiation and maintenance of the trans- 
formed state and tumorigenesis. These viral genes en- 
coded proteins that were expressed in tumor cells and 
were seen as foreign by animals harboring these tumors. 
The animals produced antibodies directed against hese 
viral antigens, and for this reason, these viral proteins 
were called tumor antigens. Accordingly, the trans- 
forming genes contained in the SV40 tumor virus were 
called the large and small tumor antigens, or T and 
t antigens. 
In 1979, David Lane and Lionel Crawford (Lane and 
Crawford, 1979)and Daniel Linzer and Arnold Levine 
(Linzer and Levine, 1979) reported that the SV40 T-anti- 
gen was bound to a cellular protein that came to be 
called p53 and that the concentration of the p53 protein 
was much higher in SV40 or other transformed cells than 
in normal cells. In fact, temperature-sensitive mutants 
of T-antigen were shown to control the levels of the p53 
protein in a temperature-sensitive fashion (Linzer et al., 
1979), and serum from animals bearing SV40-induced 
tumors contained antibodies to the p53 protein (Linzer 
and Levine, 1979). At this same time, Lloyd Old and his 
colleagues showed that animals immunized with spon- 
taneous transformed and tumorigenic ells also made 
antibodies to the p53 protein (DeLeo et al., 1979). Based 
upon these studies, p53 came to be classified as a tumor 
antigen. These observations were the first clue to the 
mechanism of how the SV40 tumor antigen might trans- 
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form cells and the next step in this investigation was to 
clone the gene for p53. 
Several groups raced to obtain the p53 cDNA, and 
Moshe Oren took on this challenge in the Levine labora- 
tory. In 1983 (Oren and Levine, 1983), he succeeded 
in using immunopurified polysomes to isolate a cDNA 
containing a portion of the 3' untranslated region of the 
p53 mRNA. This fragment was used to hybrid select 
the P53 mRNA that was then translated in vitro and 
immunoprecipitated using p53 antibodies (this assay 
was the state of the art at the time). As Moshe Oren 
went back to the Weizmann Institute to start his own 
laboratory, his group and the Levine laboratory rushed 
to create or find a cDNA library that might have a full- 
length clone of the p53 cDNA (not at all the state of the 
art at that time). The Levine laboratory approached Art 
Levinson at Genentech (previously a graduate student 
in the Levine lab), and he passed the project onto David 
Goeddell's lab, where one of their top cDNA cloners, 
Dianne Pennica, used mRNA from mouse F9 teratocarci- 
noma cells, isolated by Nancy Reich, to make a cDNA 
library that indeed had a full-length clone of p53 (Pennica 
et al., 1984). At the time, nobody thought that p53 was 
going to be important enough to patent the cDNA clone, 
since SV40 transformation was not considered to be as 
good a model for human cancer as were oncogenes 
from the RNA tumor viruses. Back at the Weizmann 
Institute, Moshe Oren employed a mouse liver genomic 
library (which, in hindsight, was apparently contami- 
nated by some clones from a transformed cell library) 
to find a full-length p53 gene (Bienz et al., 1984). A 
comparison of the amino acid sequences predicted by 
the Oren genomic clone and the Pennica cDNA clone 
showed that they were identical except at amino acid 
position 135 (out of 390 amino acids), where Oren had 
a valine and Pennica had an alanine. Not much was 
made of this difference at the time. 
The next step in this adventure was to determine if 
p53 was an oncogene that could transform cells. At the 
time there were two kinds of oncogenes: those that 
could immortalize cells in culture but had no impact 
upon the other properties of the transformed phenotype 
(myc, E1A), and those (ras, E1 B) that could fully trans- 
form permanent cell lines, but could only transform pri- 
mary cells in culture when added to these cells along 
with myc or EIA (Land et al., 1983). At this time, Cathy 
Finlay, a postdoctoral fellow who obtained her degree 
at the Wistar Institute working on cellular senescence, 
and Phil Hinds, a new graduate student, joined the Lev- 
ine laboratory and began working on the transforming 
properties of the p53 cDNA clone we had isolated. When 
our cDNA clone had no transforming activity that we 
could observe, we were a bit surprised, but we were 
even more troubled by our negative result when it was 
shown by Moshe that his p53 genomic clone plus ras 
cDNA clones could transform primary rat embryo fibre- 
blasts (Eliyahu et al., 1984). Further, two additional abs 
had similar results with different p53 clones (Jenkins et 
al., 1984; Parada et al., 1984). At this point, we ex- 
changed clones with Moshe and could easily reproduce 
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his results with his clone, and so the 135 alanine-to- 
vaiine difference began to loom larger. The trouble was, 
we didn't know whether this difference was a harmless 
polymorphism, whether a mutation at codon 135 acti- 
vated or inactivated p53's transforming ability (nor in- 
deed which sequence was wild-type), nor even whether 
the presence of introns in the transforming Oren geno- 
mic clone might produce a more active splice variant. 
What complicated our thinking at first was that our cDNA 
clone came from a teratocarcinoma library (and turned 
out to be wild-type) and Moshe's clone came from nor- 
mal mouse liver (and turned out to be a mutant). 
Careful mapping and marker rescue experiments (this 
was before the advent of PCR) by Phil Hinds solidly 
established the nontransforming F9 sequence as wild- 
type and identified the va1135 mutation as required for 
transformation by the Oren genomic construct (Hinds 
et al., 1989). Further, we began to appreciate the fact 
that most transformed cell lines in culture contain a 
diverse set of mutant p53 proteins and all teratocarci- 
noma cell lines or tumors contain a wild-type p53 protein 
(see Lutzker and Levine, 1996). Our first real clue to the 
significance of p53 mutation in cancer was obtained 
when Cathy Finlay carried out transformation studies 
mixing the two different p53 sequences (mutant and 
wild-type) with EIA plus ras or myc plus ras in transfor- 
mation assays. Phil Hinds then analyzed each of the 
transformed clones that came from the experiment, ex- 
amining the p53 proteins expressed in these cells to see 
if they were mutant or wild-type. These experiments 
gave rather surprising and clear-cut answers. Our wild- 
type p53 cDNA clone and a genomic clone bearing the 
wild-type sequence blocked the ability of myc plus ras 
or EIA plus ras to transform cells in culture. The few 
transformed clones that came from these experiments 
expressed myc and ras or E1A and ras but had a mutant 
p53 protein even though we had supplied sequences 
encoding wild-type p53. The only transformed cells that 
survived this experiment had selected for a mutant p53. 
Further, p53 cDNA clones with several different artificial 
or natural mutations could cooperate with ras and trans- 
form cells (Finlay et al., 1988) or even aided EIA plus 
ras transformation (Finlay et al., 1989). Thus, the P53 
wild-type gene was acting like an anti-oncogene or tu- 
mor suppressor gene in these assays. When coupled 
with observations of a similar mutational spectrum of 
p53 in murine erythroleukemias (Ben David et al., 1988; 
Munroe et al., 1988), these data indicated to us that the 
p53 mutant protein had lost tumor suppressor activity 
and at the same time could act upon overexpression as 
a dominant-negative p53 mutant to inactivate endoge- 
nous wild-type p53 in primary cells and cooperate with 
ras in transformation. As we were wdting the manuscript 
describing these studies (Finlay et al., 1989), we appreci- 
ated the rather complete reversal of interpretations in 
the field that this brought about; p53 began its life as a 
tumor antigen. It then was classified as an oncogene 
that could immortalize cells and cooperate with ras. Now 
the wild-type gene was going to be shown to be a tumor 
suppressor, leading to the consequent realization that 
SV40 transforms cells by inactivating the p53 protein 
function (Finlay et al., 1989). 
After the paper about all this was submitted to Cell 
and in review, A. Levine went to a Cold Spdng Harbor 
meeting held at the Banbury Center to talk about this 
work. It was at that meeting that B. Vogelstein presented 
results demonstrating that two colon cancers from hu- 
mans contained point mutations in one copy of the P53 
gene and that the other allele was lost (Baker et al., 
1989). This was a completely different path to the same 
conclusion that P53 was a tumor suppressor gene. But 
more than that, Vogelstein had shown that the p53 gene 
plays a role in human cancers. Research spanning the 
1990s and into the 21 st century has shown this to be quite 
correct. P53 mutations are common in human cancers 
(55% of human cancers), and families have now been 
identified that inherit p53 mutations and develop can- 
cers with 100% penetrance (Vogelstein et al., 2000). The 
p53 protein has been shown to be a transcription factor 
regulating a set of genes that can mediate cell cycle 
arrest and apoptosis, facilitate DNA repair, or alter other 
cellular processes. The function of the p53 protein is to 
act as a checkpoint responding to a wide variety of 
stress signals that can originate from external or internal 
events. DNA damage, hypoxia, heat shock (denatured 
proteins), mitotic spindle damage, nucleoside triphos- 
phate pool sizes, nitric oxide signaling, and even onco- 
gene mutational activation in a cell, will all signal to p53 
and elicit a specific response by the cell (Vogelstein et 
al., 2000). The p53 protein functions as an integrator of 
upstream signals and then acts as a central node in a 
signal transduction network that responds to minimize 
mutations and other errors that can lead to cancers 
or other pathologies (Vogelstein et al., 2000). In recent 
years, the regulation of the p53 protein (the central node 
in this network) has been a large part of the focus of 
this field, and this network will serve as a model for 
integrative biology and the evolution of cellular net- 
works. Many additional oncogenes and tumor suppres- 
sor genes reside in this network, and it clearly plays a 
central role in our present day understanding of cancer 
in humans. 
This review of the history of these experiments is a 
good example of how science moves ahead in a path 
that is often torturous, with many false leads and dead 
ends. It is clear, however, that progress is made because 
there are many scientists and many laboratodes that 
add key observations to a field and that these are used 
to build a structure upon which the next advance is 
made. The p53 field, which began in 1979, has benefited 
from hundreds of laboratories, sharing reagents and 
ideas, producing thousands of papers - some subset 
of which will make an important impact upon patients 
and their diseases. This all began with the conviction 
that the study of simple model systems, the DNA and 
RNA tumor viruses, could well lead to the understanding 
of the origins of cancer in humans. These virus groups 
lead us to the tumor suppressor genes and the onco- 
genes. While we have more to learn, we have made a 
good start. 
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Summary 
DNA clones of the wild-type p53 proto-oncogene in- 
hibit the ability of E1A plus ras or mutant p53 plus ras- 
activated oncogenes to transform primary rat embryo 
fibroblasts. The rare clones of transformed loci that 
result from E1A plus ras plus wi ld-type p53 triple 
transfections all contain the p53 DNA in their genome, 
but the great majority fail to express the p53 protein. 
The three cell lines derived from such foci that express 
p53 all produce mutant p53 proteins with properties 
similar or identical to transformation-activated p53 
proteins. The p53 mutants selected in this fashion 
(transformation in vitro) resemble the p53 mutants 
selected in tumors (in vivo). These results suggest 
that the p53 proto-oncogene can act negatively to 
block transformation. 
Introduction 
The proto-oncogene product, p53, is a cellular protein ex- 
pressed at low levels in nontransformed cells (Dippold et 
al., 1981; Benchimol et al., 1982; Thomas et al., 1983; 
Rogel et al., 1985). In contrast, in tumor-derived and trans- 
formed cell lines, the levels of p53 are often elevated 
(Crawford et al., 1981; Dippold et al., 1981; Benchimol et 
al., 1982; Rotter, 1983; Thomas et al., 1983; Koeffler et al., 
1986). In particular, in cells transformed by SV40 or 
adenovirus type 5, p53 is found in stable complexes with 
the transforming proteins from these viruses, the SV40 
large T antigen (Lane and Crawford, 1979; Linzer and Le- 
vine, 1979), and the E1B-55kd protein, respectively (Sar- 
now et al., 1982). The levels of p53 in cells containing 
these complexes are approximately 100-fold higher than 
in the nontransformed cell, and the half-life of p53 is cor- 
respondingly extended (from 20 min to 24 hr) (Oran et al., 
1981; Reich et al., 1983). Therefore, the elevation of p53 
levels has often been correlated with cellular transforma- 
tion. The results of several studies have supported the hy- 
pothesis that increased levels of p53 effect changes in the 
phenotype of the normal cell; overexpression of p53 
resulted in the immortalization of rodent cells (Jenkins et 
al., 1984; Rovinski and Benchimol, 1988) and, when as- 
sayed in conjunction with an activated ms gene, in the full 
transformation of primary rodent cells to a tumorigenic 
phenotype (Eliyahu et al., 1984; Parada et al., 1984). Re- 
cent studies, however, have demonstrated that the wild- 
type sequence of the proto-oncogene p53 (p53-wt) does 
not encode a transforming protein; i.e., no transformants 
are observed when primary rat embryo fibroblasts are 
cotransfected with a p53-wt plus an activated ras gene 
(Finlay et al., 1988; Eliyahu et al., 1988; Hinds et al., 1989). 
The confusion surrounding the transforming activities of 
p53 resulted from the existence of several independently 
derived p53 cDNAs and of at least one p53 genomic 
clone, all of which possess mutations that activate the p53 
protein for cooperation with ras (Finlay et al., 1988; 
Eliyahu et al., 1988; Hinds et al., 1989). The mutations (the 
result of one or two single nucleotide changes) are local- 
ized between amino acids 130 and 234 (out of a total of 
390 amino acids). In addition, linker insertion mutations 
in this same region also activate the p53 protein for trans- 
formation with the ras oncogene (Finlay et al., 1988). In 
general, the activated p53 proteins have several proper- 
ties in common: they bind poorly or not at all to the SV40 
large T antigen; they form complexes with the constitu- 
tively expressed member of the 70 kd heat shock family, 
hsc70; and they do not express an epitope localized be- 
tween amino acid residues 88 and 109 that is recognized 
by the murine-speciflc, conformation-dependent, mono- 
clonal antibody PAb246. These transformation-activating 
mutations span a region comprising approximately 25% 
of the p53 protein. These observations suggest that the 
transformation-activating mutations could result from a 
loss-of-function mutation of the p53 protein. These mu- 
tants, when overexpressed, could then act in a trans- 
dominant fashion to inactivate the endogenous wild-type 
p53, perhaps by the formation of nonfunctional multimeric 
complexes of proteins (Herskowitz, 1987). It has previ- 
ously been clearly demonstrated that high levels of mutant 
p53 proteins are required for the efficient cloning and es- 
tablishment of p53 plus ras - t ransformed cell lines (Hinds 
et al., 1989). The association between mutant p53 pro- 
teins and the endogenous wild-type p53 protein in a com- 
plex has also been previously observed (Rovinski and 
Benchimol, 1988; Eliyahu et al., 1988). Thus, inactivation 
of the p53-wt protein by an inactive mutant p53 protein in 
the same complex may actually be involved in the process 
of p53-mediated transformation. 
The inactivation of p53 appears to play an important role 
in the development of Friend virus-induced erythroleuke- 
mias in vivo. Rearrangement of the murine p53 gene oc- 
curs in a high proportion of malignant cell lines derived 
from the spleens of Friend virus-infected mice (Mowat et 
al., 1985; Chow et al., 1987), resulting in the inactivation 
of p53 (Ben-David et al., 1988) or the synthesis of elevated 
levels of antigenically related truncated polypeptides 
(Rovinski et al., 1987; Munroe et al., 1988). These investi- 
gators have suggested that the inactivation of the p53 
gene confers a selective advantage for the development 
of the tumorigenic phenotype. The rearrangement of the 
p53 gene has also been observed in 3/6 human osteo- 
genic sarcomas (Masuda et al., 1987). 
The inactivation of p53 functions could also be involved 
in the process of viral transformation. Recent studies have 
demonstrated that both the SV40 large T antigen and the 
EIA products from Ad5 form specific complexes with the 
